Only one qualitative study has been conducted to date investigating patients taking GLP-1 receptor agonists [31], which focussed on reasons for adherence to the medication
6 Multi-agonist strategies are increasingly being studied, some of which include dual GLP-1/GIP agonists like tirzepatide and triple agonists that target GLP-1, GIP, and glucagon-like retatrutide
Second, although SGLT2i monotherapy has been linked to improvements in fatty liver index and lower risk of MALO in MASLD patients, 12,15,28,29,30 , our findings suggest that adding GLP-1RA to SGLT2i provided additional hepatic benefits, reducing the risk of MALO by 39%
Greece: PM Publications
A hippocampus to prefrontal cortex neural pathway inhibits food motivation through glucagon-like peptide-1 signaling
G-LEVOCARNITINE - Uses, Side Effects, and More